Beneficial Effects of C36, a Novel Breaker of Advanced Glycation Endproducts Cross-links, on the Cardiovascular System of Diabetic Rats

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2007 Oct 30

PMID 17965740

Citations 11

Authors

G Cheng

L-L Wang

L Long

H-Y Liu

H Cui

W-S Qu

S Li

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Advanced glycation endproducts (AGE) have been implicated in the pathogenesis of diabetic complications, including diabetic cardiovascular dysfunctions. 3-benzyloxycarbonylmethyl-4-methyl-thiazol-3-ium bromide (C36), a novel AGE breaker, was investigated for its beneficial effects on the cardiovascular system of diabetic rats.

Experimental Approach: The in vitro breaking abilities of C36 on AGE cross-links formed in vitro and in vivo were assessed. After 4 weeks' treatment with C36, cardiovascular and left ventricular functions in diabetic (streptozotocin-induced) rats were evaluated by haemodynamic studies. Effects of C36 on AGE accumulation, collagen distribution, and fibrosis-associated gene expression were also investigated by biochemical and morphological methods and reverse transcription-PCR, respectively.

Key Results: In vitro, C36 released bovine serum albumin (BSA) from preformed AGE-BSA-collagen complexes and decreased the IgG cross-linked to red blood cell surface (RBC-IgG). In vivo, C36 treatment of diabetic rats resulted in a significant increase in left ventricular systolic pressure and the maximal rate of left ventricular pressure rise and pressure fall, induction in cardiac output and systemic arterial compliance, decrease of total peripheral resistance, reduction of diabetes-induced RBC-IgG content, increase of myocardial and tail tendon collagen solubility, and normalization of collagen type III/I ratio in diabetic rats. In addition, C36 treatment attenuated mRNA levels of diabetes-induced genes, including receptors for AGE, transforming growth factor beta1, connective tissue growth factor, and collagen III.

Conclusions And Implications: C36 was an effective breaker of AGE cross-links and had beneficial effects on the cardiovascular system of diabetic rats.

Citing Articles

Advanced Glycation End Products in Health and Disease.

Reddy V, Aryal P, Darkwah E Microorganisms. 2022; 10(9).

PMID: 36144449 PMC: 9501837. DOI: 10.3390/microorganisms10091848.

Identification of a potent NAFLD drug candidate for controlling T2DM-mediated inflammation and secondary damage and .

Md Samsuzzaman , Lee J, Moon H, Lee J, Lee H, Lim Y Front Pharmacol. 2022; 13:943879.

PMID: 36059993 PMC: 9437277. DOI: 10.3389/fphar.2022.943879.

Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties.

Kim J, Kim C, Kim Y, Lee I, Kim J J Exerc Nutrition Biochem. 2017; 20(4):60-64.

PMID: 28150470 PMC: 5545203. DOI: 10.20463/jenb.2016.0049.

Dietary glycotoxins and infant formulas.

Kutlu T Turk Pediatri Ars. 2017; 51(4):179-185.

PMID: 28123329 PMC: 5242244. DOI: 10.5152/TurkPediatriArs.2016.2543.

Is increased arterial stiffness a cause or consequence of atherosclerosis?.

Hansen L, Taylor W Atherosclerosis. 2016; 249:226-7.

PMID: 27133480 PMC: 5305033. DOI: 10.1016/j.atherosclerosis.2016.04.014.

References

Twigg S, Cao Z, MCLennan S, Burns W, Brammar G, Forbes J . Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology. 2002; 143(12):4907-15. DOI: 10.1210/en.2002-220619. View

Candido R, Forbes J, Thomas M, Thallas V, Dean R, Burns W . A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003; 92(7):785-92. DOI: 10.1161/01.RES.0000065620.39919.20. View

Yan S, Schmidt A, Anderson G, Zhang J, Brett J, Zou Y . Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994; 269(13):9889-97. View

Twigg S, Joly A, Chen M, Tsubaki J, Kim H, Hwa V . Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology. 2002; 143(4):1260-9. DOI: 10.1210/endo.143.4.8741. View

Yin F, Guzman P, Brin K, Maughan W, Brinker J, Traill T . Effect of nitroprusside on hydraulic vascular loads on the right and left ventricle of patients with heart failure. Circulation. 1983; 67(6):1330-9. DOI: 10.1161/01.cir.67.6.1330. View

Cheng G, Wang L, Qu W, Long L, Cui H, Liu H . C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats. Acta Pharmacol Sin. 2005; 26(12):1460-6. DOI: 10.1111/j.1745-7254.2005.00240.x. View

Avendano G, Agarwal R, BASHEY R, LYONS M, Soni B, Jyothirmayi G . Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes. 1999; 48(7):1443-7. DOI: 10.2337/diabetes.48.7.1443. View

Makita Z, Vlassara H, Cerami A, Bucala R . Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem. 1992; 267(8):5133-8. View

Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A . Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986; 232(4758):1629-32. DOI: 10.1126/science.3487117. View

10.

Stern D, Yan S, Yan S, Schmidt A . Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev. 2002; 54(12):1615-25. DOI: 10.1016/s0169-409x(02)00160-6. View

11.

Shimizu M, Umeda K, Sugihara N, YOSHIO H, Ino H, Takeda R . Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol. 1993; 46(1):32-6. PMC: 501107. DOI: 10.1136/jcp.46.1.32. View

12.

Kochakian M, Manjula B, Egan J . Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes. 1996; 45(12):1694-700. DOI: 10.2337/diab.45.12.1694. View

13.

Bruel A, Oxlund H . Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Atherosclerosis. 1996; 127(2):155-65. DOI: 10.1016/s0021-9150(96)05947-3. View

14.

Coughlan M, Thallas-Bonke V, Pete J, Long D, Gasser A, Tong D . Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. Endocrinology. 2006; 148(2):886-95. DOI: 10.1210/en.2006-1300. View

15.

Monnier V, Kohn R, Cerami A . Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A. 1984; 81(2):583-7. PMC: 344723. DOI: 10.1073/pnas.81.2.583. View

16.

Levy B, Duriez M, Phillipe M, POITEVIN P, Michel J . Effect of chronic dihydropyridine (isradipine) on the large arterial walls of spontaneously hypertensive rats. Circulation. 1994; 90(6):3024-33. DOI: 10.1161/01.cir.90.6.3024. View

17.

Murphy M, Godson C, Cannon S, Kato S, Mackenzie H, Martin F . Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem. 1999; 274(9):5830-4. DOI: 10.1074/jbc.274.9.5830. View

18.

Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J . An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996; 382(6588):275-8. DOI: 10.1038/382275a0. View

19.

Schmidt A, Yan S, Yan S, STERN D . The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001; 108(7):949-55. PMC: 200958. DOI: 10.1172/JCI14002. View

20.

Norton G, Candy G, Woodiwiss A . Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation. 1996; 93(10):1905-12. DOI: 10.1161/01.cir.93.10.1905. View